We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Momentum is building on Capitol Hill for legalizing
the importation of pharmaceuticals into the U.S., says the head of the Senate
health panel that would shepherd through any authorizing legislation.
Medicare should quickly adopt a comprehensive electronic prescribing system
based on a technologically advanced uniform national standard to realize the
full benefits of eprescribing under the new Medicare prescription drug benefit,
the Pharmaceutical Care Management Association (PCMA) recently told the Centers
for Medicare & Medicaid Services (CMS).
Questcor Pharmaceuticals, a specialty pharmaceutical company, announced its
new business strategy and therapeutic focus. The company will now focus exclusively
on developing and commercializing products that treat diseases and disorders
of the central nervous system (CNS).
Evotec OAI AG, a leader in integrated high-value-added drug discovery and development,
Wednesday said it has extended its global discovery chemistry agreement with
Roche Holding signed in May 2004 for a further 12 months. Evotec OAI has a long-standing
relationship with Roche.
Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and Benitec
Ltd., a leading developer of DNA-directed RNA interference therapeutics, announced
a licensing agreement covering fundamental intellectual property (IP) in the
field of RNA interference (RNAi).
Xencor announced that Eli Lilly and Company has exercised its option to develop
one or more therapeutic proteins created by Xencor under its collaboration with
Lilly.
Auxilium Pharmaceuticals and Oscient Pharmaceuticals Corporation have signed
a co-promotion partnership to promote Auxilium's marketed product, Testim 1
percent testosterone gel, for the treatment of hypogonadism in the U.S., to
a significantly larger group of primary care physicians beyond those already
called upon by Auxilium.
Seattle Genetics licensed exclusive rights to a potential anticancer therapy
from Protein Design Labs Inc. Biotechnology company Seattle Genetics said in
a press release Wednesday that it will receive rights to Protein Design's anti-CD33
program for both unconjugated antibody and antibody-drug conjugate applications,
associated U.S. patents and patent applications.
Kos Pharmaceuticals and Barr Pharmaceuticals announced that that they have signed
co-promotion, licensing and manufacturing, and settlement and license agreements
relating to the resolution of the patent litigation involving Kos' Niaspan products.
Licensing and acquiring products will be the focus
for King Pharmaceuticals Incorporated of Bristol. King president Brian Markison
says the company is being transformed following a botched $4 billion merger
with Mylan Laboratories Incorporated earlier this year.